NASDAQ:SNOA

Sonoma Pharmaceuticals Q3 2025 Earnings Results & Report

Sonoma Pharmaceuticals logo
$0.72 -0.09 (-10.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.69%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals reported Q3 2025 earnings on February 5, 2025. The company reported EPS of -$0.59.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.59
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Sonoma Pharmaceuticals Q3 2025 Earnings FAQ

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported earnings of -$0.59 per share for Q3 2025. The report was announced on Wednesday, February 5, 2025.

Sonoma Pharmaceuticals Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications.

The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets.

The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Its business has since focused on developing and commercializing hypochlorous acid-based products for healthcare and related markets.

View Sonoma Pharmaceuticals Profile